• 6% of current sales expected over 12 months
• Meaningful, long-term and recurring revenue contribution
• Diversifies customer base and aligns with growth strategy

Genetic Signatures Ltd (ASX: GSS) has provided additional information on its previously announced Danish supply agreement. Over a 12-month period, sales from the Hvidore supply agreement are expected to represent approximately 6% of the Company's current sales, based on estimated testing volumes and agreed pricing. The Board considers the agreement to be meaningful to the Company's operations, providing a meaningful, long-term and recurring revenue contribution in the EMEA region, diversifying the customer base, and aligning with the Company's growth strategy. The contract is legally binding with no outstanding conditions, and commercial orders are expected to commence from September 2026 following customary installation and validation processes. The Company is not aware of any other material information relevant to assessing the impact of the contract on the price or value of its securities.